Publicação
Terapias antitumorais baseadas em células dendríticas
| Resumo: | Dendritic cells (DCs) are professional antigen-presenting cells and are extremely important in activating acquired immunity, as they can modulate various specific T and B cell responses. There are several subtypes of dendritic cells, which allow the body to generate different responses to each type of invading agent, through different activation cascades depending on the type of response that is intended to be generated, by the presentation of antigens through the major histocompatibility complex 1, which specializes in activating cytotoxic CD8+ T ,cells, normally, by the presentation of intracelular antigens, or by major histocompatibility complex 2, which activates effector CD4+ T cells by presenting antigens captured externally by antigen presenting cells.In addition, dendritic cells present the function to trigger a response to eliminate tumor cells, mainly by stimulating cytotoxic T lymphocytes with exogenous antigens with the ability to use crosspresentation. This ability to activate anti-tumor responses has enabled the development of immunotherapies using dendritic cells. This scientific review thesis aims to address the immunobiology of dendritic cells and their different subtypes and therapies involving these cells, with a special focus on in vivo therapy targeting DCs using monoclonal antibodies. This targeting strategy has been developed more recently and shows promising results in the fight against cancer while presenting advantages over the ex vivo use of dendritic cells. |
|---|---|
| Autores principais: | Carvalho, Miguel João Mendes Cortez de |
| Assunto: | Dendritic cells Antigen presentation T-cells Anti-tumor therapies Monoclonal antibodies Células dendríticas Apresentação de antigénios Células T Terapias antitumorais anticorpos monoclonais |
| Ano: | 2024 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade de Coimbra |
| Idioma: | português |
| Origem: | Estudo Geral - Universidade de Coimbra |
| Resumo: | Dendritic cells (DCs) are professional antigen-presenting cells and are extremely important in activating acquired immunity, as they can modulate various specific T and B cell responses. There are several subtypes of dendritic cells, which allow the body to generate different responses to each type of invading agent, through different activation cascades depending on the type of response that is intended to be generated, by the presentation of antigens through the major histocompatibility complex 1, which specializes in activating cytotoxic CD8+ T ,cells, normally, by the presentation of intracelular antigens, or by major histocompatibility complex 2, which activates effector CD4+ T cells by presenting antigens captured externally by antigen presenting cells.In addition, dendritic cells present the function to trigger a response to eliminate tumor cells, mainly by stimulating cytotoxic T lymphocytes with exogenous antigens with the ability to use crosspresentation. This ability to activate anti-tumor responses has enabled the development of immunotherapies using dendritic cells. This scientific review thesis aims to address the immunobiology of dendritic cells and their different subtypes and therapies involving these cells, with a special focus on in vivo therapy targeting DCs using monoclonal antibodies. This targeting strategy has been developed more recently and shows promising results in the fight against cancer while presenting advantages over the ex vivo use of dendritic cells. |
|---|